CEO of Sunshine Biopharma, Dr. Steve Slilaty, is Featured on The Stock Day Podcast

Phoenix, October 22nd, 2020 (Newsfile Corp.) — The Stock Day Podcast welcomed Sunshine Biopharma (SBFM) (“the Company”), a company working on the development of a treatment for COVID-19, as well as the development of Adva-27a, a unique anticancer compound. CEO of the Company, Dr. Steve Slilaty, joined Stock Day host Everett Jolly.

Jolly began the interview by asking Dr. Slilaty about the Company’s background and current projects. “Sunshine Biopharma is an R&D company and we’re focused on two areas of research. One is oncology and the second is antiviral compounds,” explained Dr. Slilaty. “In the area of oncology, we have an anticancer drug that works on multidrug resistant cancers, such as pancreatic cancer and small cell lung cancer,” he continued. “In the area of antivirals, we are working on a protease inhibitor for coronavirus.”

Jolly then asked about the difference between the Company’s compound, SBFM-PL4, and Regeneron’s. “The President [President Trump] received the monoclonal antibody cocktail that was developed by Regeneron,” explained Dr. Slilaty. “It’s very effective in that it’s able to neutralize the coronavirus in the system, however it has to be administered by injection in the hospital,” said Dr. Slilaty. “We’re working on something totally different. It’s a protease inhibitor, which will be in the form of a pill that people can take at home.”

Jolly then commented on a recent press release regarding the Company’s partnership with the University of Georgia. “How did that come about and what makes you excited about that whole process?”, asked Jolly. Dr. Slilaty elaborated on his relationship with University of Georgia’s Dr. Scott Pegan, and shared that the Company is now working with the University on the development of SBFM-PL4, for use as a treatment for coronavirus. “The University of Georgia has expertise in the area of protease inhibitors, as well as in doing the assays and mouse studies involving coronavirus.”

“How does the coronavirus attack the body?”, asked Jolly. “The alpha coronavirus causes the common cold and the beta coronavirus is referred to as SARS,” explained Dr. Slilaty, adding that out of four types of coronavirus the alpha and beta versions are the most dangerous. “These are the ones we’re working on developing inhibitors for to completely arrest the ability of these viruses to replicate in the human body,” said Dr. Slilaty. “When the virus enters the body, it immediately begins to replicate,” he explained. “Some of the proteins generated are able to shut down the immune response of the human body.”

“Where are you at in the process of bringing your SBFM-PL4 to the marketplace?”, asked Jolly. Dr. Slilaty shared that there are several companies working on vaccines and antibodies to fight the coronavirus, however the Company’s protease inhibitor is an early stage solution. “We’re very excited about it and we’re optimistic that we will be able to begin the mice studies before the end of the year,” said Dr. Slilaty.

To close the interview, Dr. Slilaty shared that the Company will remain dedicated to developing a solution for the coronavirus in an effort to have a positive impact on the world during this pandemic.

To hear Dr. Steve Slilaty’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/7711456-ceo-of-sunshine-biopharma-dr-steve-slilaty-is-featured-on-the-stock-day-podcast

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

About Sunshine Biopharma

In addition to working on the development of SBFM-PL4 as a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information:

Sunshine Biopharma, Inc.

Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com

About The “Stock Day” Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:

Stock Day Media

(602) 821-1102

SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG

For Immediate Release October 19, 2020

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has entered into an Agreement with the University of Georgia for the purposes of working together to advance the development of Sunshine Biopharma’s recently announced Anti-Coronavirus lead compound, SBFM-PL4. The goal of this cutting-edge collaboration is to develop SBFM-PL4, a protease inhibitor, as a treatment for Coronavirus infections. This new treatment is based on the technology described in Sunshine Biopharma’s recently filed patent application covering small molecules which can be used to treat Coronavirus infections. Sunshine’s SBFM-PL4, will be put through a series of in vitro tests to evaluate its specific inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro), one of two Coronavirus encoded proteases essential for viral replication. Following the initial in vitro studies, SBFM-PL4 will be moved forward to the cell culture testing stage and assessment in Coronavirus infected mice before entering human clinical trials.

“We are delighted to be working with the University of Georgia and Dr. Scott Pegan and his team of Coronavirus experts who share our vision of developing a treatment that would make a difference in the fight against the pandemic,” said Dr. Steve Slilaty, CEO of Sunshine Biopharma.

About Sunshine Biopharma’s Coronavirus Treatment

Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of COVID-19, the current ongoing pandemic that has claimed the lives of over 1,000,000 people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply and cause illness.

About the University of Georgia

As part of its land grant tripartite mission, the University of Georgia is committed to creating and applying new knowledge for the public good. UGA’s Center for Drug Discovery as well as the Colleges of Pharmacy are excited to be a part of this ground-breaking research related to discovery of new treatment options for COVID-19. Profs. Scott Pegan, and David Crich will be working with Sunshine Biopharma to spearhead the study of novel therapeutics for the

prevention and spread of COVID-19. This interdisciplinary effort involves state of the art approaches in chemical synthesis and drug screening. This continues University of Georgia’s long-standing tradition in translating scientific breakthroughs to address real world health concerns.

About Sunshine Biopharma

In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.

Safe Harbor Forward-Looking Statements

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term. Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of which cannot be predicted at this time.

For Additional Information:

Sunshine Biopharma, Inc. Camille Sebaaly, CFO

Direct Line: 514-814-0464

camille.sebaaly@sunshinebiopharma.com

www.sunshinebiopharma.com

SUNSHINE BIOPHARMA IDENTIFIES A LEAD ANTI-CORONAVIRUS COMPOUND

For Immediate Release – October 7, 2020.

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFM”), a
pharmaceutical company focused on the research, development and commercialization of
oncology and antiviral drugs today announced that it has screened and subsequently identified
a lead compound from its library of Coronavirus protease inhibitors. The screening which
pinpointed the lead compound was performed at the University of Georgia, College of Pharmacy
under the leadership of Dr. Scott D. Pegan, Director of the Center for Drug Discovery and
Interim Associate Head of Pharmaceutical and Biomedical Sciences. The Company is currently
looking into expanding its collaboration with the University of Georgia and will be seeking the
University’s assistance in advancing the development of the newly identified lead compound.
The compounds which were screened are based on the technology described in Sunshine
Biopharma’s recently filed patent application covering small molecules which can be used to
treat Coronavirus infections. Next, Sunshine’s lead compound will be put through a battery of in
vitro tests to evaluate its specific inhibitory activity against the SARS-CoV-2 papain-like
protease (PLpro), one of two virus encoded proteases essential for viral replication. In addition
to cleaving the virus encoded polyprotein at three different sites to generate mature virus
proteins, PLpro also cleaves certain host proteins resulting in suppression of the host immune
response and allowing virus replication to proceed unchecked which enhances the virus’ ability
to cause severe morbidity. Following the in vitro tests, the lead compound will be moved forward
to the cell culture testing stage followed by mice studies before entering human clinical trials.


About Sunshine Biopharma’s Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of
COVID-19, the current ongoing pandemic that has claimed the lives of over 1,000,000 people
worldwide since it first appeared in December 2019. There are currently no drugs that can
effectively arrest replication of the virus in people who have contracted the illness. On May 22,
2020, Sunshine Biopharma filed a provisional patent application for a library of molecules which
were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to
multiply and cause illness.


About the University of Georgia

As part of its land grant tripartite mission, the University of Georgia is committed to
creating and applying new knowledge for the public good. UGA’s Center for Drug Discovery as
well as the Colleges of Pharmacy are excited to be a part of this ground-breaking research
related to discovery of new treatment options for COVID-19. Profs. Scott Pegan, and David
Crich will be working with Sunshine Biopharma to spearhead the study of novel therapeutics for
the prevention and spread of COVID-19. This interdisciplinary effort involves state of the art
approaches in chemical synthesis and drug screening. This continues University of Georgia’s
long-standing tradition in translating scientific breakthroughs to address real world health
concerns.


About Sunshine Biopharma
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to
date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant
Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer
cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to
be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine
Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.


Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and
assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ
materially from those anticipated or expected, including statements related to the amount and timing of expected
revenues statements related to our financial performance, expected income, distributions, and future growth for
upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by
the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain
events could differ materially from those projected in or contemplated by the forward-looking statements due to a
number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not
be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock
market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC
filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as
new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the
near and long term. Additional service offerings may expose us to additional legal and regulatory costs and
unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of
which cannot be predicted at this time.


For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

SUNSHINE BIOPHARMA SECURES $2,000,000 FINANCING FOR CORONAVIRUS TREATMENT

For Immediate Release – September 15, 2020.

Montreal, Quebec, Canada — (ACCESSWIRE) — Sunshine Biopharma Inc. (OTC Markets:
“SBFM”), a pharmaceutical company focused on the research, development and
commercialization of oncology and antiviral drugs, today announced that it has received the first
tranche of $250,000 as part of a committed minimum financing of $2 Million with RB Capital
Partners Inc. (“RB Capital”). Pursuant to the financing agreement entered into as of September
8, 2020, RB Capital has agreed to provide funding to the Company in the form of convertible
promissory notes (the “Promissory Notes”). The Promissory Notes will bear interest at the rate
of 5% per annum and will be fully convertible into shares of the Company’s Common Stock at a
conversion price equal to the market value of the Company’s Common Stock on the applicable
conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a
maturity date of two years from the date of issuance and must be fully converted on or before
the maturity date. Sunshine reserves the right to pay off any part or all of the Promissory Notes
at any time without penalty. The minimum amount of funding that RB Capital has agreed to
provide to the Company under these terms is $2,000,000, payable over the next three to six
month period.


The proceeds will be used for development of the Company’s recently announced Coronavirus
treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship
anticancer compound targeted for pancreatic cancer.


Sunshine Biopharma’s CFO, Camille Sebaaly stated, “We are extremely pleased to have forged
a relationship with RB Capital and believe that this is the beginning of a successful funding
partnership. We are now well positioned to continue with the development of our life saving
treatments with a funding partner alongside of us who sees the long-term vision of the
Company.”


About Sunshine Biopharma’s Coronavirus Treatment
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of
COVID-19, the current ongoing pandemic that has claimed the lives of over 920,000 people
worldwide since it first appeared in December 2019. There are currently no drugs that can
effectively arrest replication of the virus in people who have contracted the illness. On May 22,
2020, Sunshine Biopharma filed a provisional patent application for several molecules which
were designed by computer-aided modeling to inhibit the Coronavirus proteases, thus shutting
down the ability of the virus to multiply. More recently, Sunshine Biopharma announced that it
has completed the synthesis of four such molecules and is currently testing their inhibitory
activity on SARS-Cov-2 proteases in order to identify a lead compound for further development
as a specific drug for treatment of COVID-19.


About Sunshine Biopharma’s Adva-27a Anticancer Compound
In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is
engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to
date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant
Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer
cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to
be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine
Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.


Safe Harbor Forward-Looking Statements
This press release may contain forward looking statements which are based on current expectations, forecasts, and
assumptions that involve risks as well as uncertainties that could cause actual outcomes and results to differ
materially from those anticipated or expected, including statements related to the amount and timing of expected
revenues statements related to our financial performance, expected income, distributions, and future growth for
upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by
the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain
events could differ materially from those projected in or contemplated by the forward-looking statements due to a
number of factors detailed from time to time in our filings with the SEC. Among other matters, the Company may not
be able to sustain growth or achieve profitability based upon many factors including but not limited to general stock
market conditions. Reference is hereby made to cautionary statements set forth in the Company’s most recent SEC
filings. We have incurred and will continue to incur significant expenses in our expansion of our existing as well as
new service lines noting there is no assurance that we will generate enough revenues to offset those costs in both the
near and long term. Additional service offerings may expose us to additional legal and regulatory costs and
unknown exposure(s) based upon the various geopolitical locations we will be providing services in, the impact of
which cannot be predicted at this time.


For Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma Inc.
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

SUNSHINE BIOPHARMA COMPLETES THE SYNTHESIS OF FOUR POTENTIAL INHIBITORS OF CORONAVIRUS PROTEASE

For Immediate Release, August 25, 2020.

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Markets: “SBFM”), a
pharmaceutical company focused on the research, development and commercialization of
oncology and antiviral drugs today announced that it has completed the synthesis of four
different potential inhibitors of Coronavirus protease. These compounds are based on the
technology described in the Company’s recently filed patent application covering small
molecules which can be used to treat Coronavirus infections, including SARS-CoV-2 the
causative agent of COVID-19. Next, Sunshine will evaluate the binding affinity of these
molecules to the SARS-CoV-2 papain-like protease (PLpro), one of two virus encoded
proteases essential for viral replication. In addition to cleaving the virus encoded polyprotein at
three different sites to generate mature virus proteins, PLpro also cleaves certain host proteins
resulting in suppression of the innate immune response thereby allowing the virus to multiply
unhindered. Based on the binding affinity results, Sunshine will select a lead compound for
further Anti-Coronavirus drug development.


About Sunshine Biopharma
Sunshine Biopharma is a pharmaceutical company focused on the research, development, and
commercialization of oncology and antiviral drugs. In addition, to working on the development of
a treatment for COVID-19, Sunshine biopharma is engaged in the development Adva-27a, a
unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of
Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells,
Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for
Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General
Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual
property pertaining to Adva-27a and the Coronavirus protease inhibitors under development.


Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to
revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals,
future financial conditions, future collaboration agreements, the success of the Company’s development,
events conditioned on stockholder or other approval, or otherwise as to future events, such statements
are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to
certain risks and uncertainties that could cause actual results to differ materially from the statements
made.


For Additional Information:
Sunshine Biopharma, Inc.

Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A NEW CORONAVIRUS COVID-19 TREATMENT

Montreal, Canada – (ACCESSWIRE) – Sunshine Biopharma Inc. (OTC Pink Sheets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer today announced that it has filed a patent application in the United States for a new treatment for Coronavirus infections, including COVID-19. Sunshine’s patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. The patent application has a priority date of May 22, 2020.

“The causative agent of the current COVID-19 global pandemic is Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), one of several strains of Coronavirus capable of infecting humans and causing serious illness. SARS-CoV-2 produces several functional proteins in infected human cells by cleaving them from two overlapping viral ‘polyproteins,’ pp1a and pp1ab. One of these functional proteins is a cysteine protease referred to as the main protease (Mpro, also called 3CLpro and nsp5). Mpro cleaves the viral ‘polyproteins’ at a number of specific sites thereby generating a multi-subunit protein complex termed ‘viral replicase-transcriptase’. Because of its functional indispensability in viral replication, Mpro is an attractive drug target for the development of a treatment for COVID-19 and other Coronavirus infections,” said Dr. Slilaty.


Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

Sunshine Biopharma Receives Health Canada Approval for Essential Calcium-Vitamin DTM Supplement

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”) today announced that it has received Health Canada approval for Essential CalciumVitamin DTM supplement, the second in a line of Essential Micronutrients Products that the Company is planning to launch. Health Canada issued NPN 80093432 through which it authorized Sunshine Biopharma to manufacture and sell a Calcium-Vitamin D supplement under the brand name Essential Calcium-Vitamin .

Essential Calcium-Vitamin DTM is a dietary supplement tablet that contains a balanced formula of Calcium and Vitamin D complex. Vitamin D plays a major role in multiple biological functions, including regulating the concentration of calcium and phosphate, and promoting the healthy growth and remodeling of bone. In addition, Vitamin D is involved in cell growth, neuromuscular and immune functions, and reduction of inflammation. Sunshine Biopharma anticipates that Essential Calcium-Vitamin DTM will be available on Amazon.ca in January 2020. The Company’s first Essential Micronutrients Product, Essential 9TM , launched earlier this year is currently available in Canada on Amazon.ca and in the US on Amazon.com. About Essential Calcium Vitamin DTM
Vitamin D is a group of steroid-like molecules responsible for increasing intestinal absorption of calcium, magnesium, and phosphate. They are also involved in multiple other biological
functions, including promoting the healthy growth and remodeling of bone, cell growth, neuromuscular and immune functions, and reduction of inflammation. The most important
compounds in this group are Vitamin D2 (ergocalciferol) and Vitamin D3 (cholecalciferol).


Sunshine Biopharma’s Essential Calcium-Vitamin DTM tablets contain both of these compounds as well as Calcium for optimum health benefits. About Essential 9TM
Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and
neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids
can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9TM provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. Essential 9TM is suitable for everyone: vegans, athletes, seniors, dieters. Essential 9tm is currently available on Amazon.ca and Amazon.com.

Safe Harbor Forward-Looking Statements To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.


For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

SUNSHINE BIOPHARMA INITIATES Adva-27a XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of aggressive forms of cancer, today announced that it has initiated studies of Adva-27a in xenograft mice. In these studies, specifically engineered mice which have developed tumors following injection with patient derived cancer cells are treated with Adva-27a to assess the ability of the drug to shrink the tumors. Among the different types of patient derived cancer types being studied are Pancreatic Cancer, Breast Cancer, Small-Cell Lung Cancer and Uterine Sarcoma.

About Adva-27a
Adva-27a is Sunshine Biopharma’s proprietary anticancer compound. In vitro tests conducted on Adva-27a have demonstrated the drug’s effectiveness at destroying Multidrug Resistant Cancer Cells including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a. Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:
We are pleased to announce that we have created additional ways of interacting with our team.
Please visit our new website and join us at:
https://twitter.com/Sunshine_Pharma
https://t.me/SunshineBiopharma
Or contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
info@sunshinebiopharma.com
www.sunshinebiopharma.com

Sunshine Biopharma Receives Vegan Certification for Essential 9 Amino Acids Supplement

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”) today announced that it has received Vegan Certification for Essential 9TM from VegeCert.com in association with KASHRUTH COUNCIL OF CANADA. In December 2018, Health Canada issued NPN 80089663 through which it authorized Sunshine Biopharma to manufacture and sell the Essential 9TM product. Essential 9TM is dietary supplement tablets that contain a balanced formula of the 9 essential amino acids that the human body cannot make. Essential 9TM is currently available on Amazon.com and Amazon.ca.


About Essential 9TM
Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9TM provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. Essential 9TM is suitable for everyone: vegans, athletes, seniors, dieters.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com

In Addition to Essential 9TM, Sunshine Biopharma Launches 7 New Dietary Supplements Now Available on Amazon.ca

Montreal, Quebec, Canada – (ACCESSWIRE) – Sunshine Biopharma, Inc. (OTC Markets: “SBFM”) today announced that it has launched 7 new dietary supplements in addition to its original product, Essential 9TM. The new products are:

  • BCAA (Helps improve muscle growth and reduce muscle soreness and exercise fatigue)
  • L-Carnitine (Helps improve energy production, and muscle and brain functions, especially in older adults, vegans and vegetarians)
  • L-Creatine (Beneficial for both athletic performance and general health, including brain and other neurological functions)
  • L-Glutamine (Provides energy support for the immune system and intestinal cells)
  • Vitaminax (Multivitamins, Minerals & Antioxidants Chewable Tablets)
  • Omega 3 (1000 mg Softgels)
  • Vitamin B12 (Chewable Tablets)

These together with Essential 9TM are available on www.Amazon.ca. Currently, only Essential 9TM is available in the United States on www.Amazon.com.


About Essential 9TM
Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – from the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, fatigue, weight gain and reduced ability to build muscle mass in athletes. Sunshine Biopharma’s Essential 9TM provides all 9 Essential Amino Acids in freeform and in the proportions recommended by Health Canada. Essential 9TM is suitable for everyone: vegans, athletes, seniors, dieters.


Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company’s development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

For Additional Information:
Sunshine Biopharma, Inc.
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com